vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and TEXAS CAPITAL BANCSHARES INC (TCBI). Click either name above to swap in a different company.
TEXAS CAPITAL BANCSHARES INC is the larger business by last-quarter revenue ($324.0M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). TEXAS CAPITAL BANCSHARES INC runs the higher net margin — 22.8% vs 1.6%, a 21.1% gap on every dollar of revenue. On growth, TEXAS CAPITAL BANCSHARES INC posted the faster year-over-year revenue change (15.5% vs 5.0%). Over the past eight quarters, TEXAS CAPITAL BANCSHARES INC's revenue compounded faster (10.2% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
PCRX vs TCBI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $324.0M |
| Net Profit | $2.9M | $73.8M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | 22.8% |
| Revenue YoY | 5.0% | 15.5% |
| Net Profit YoY | — | 56.8% |
| EPS (diluted) | $0.07 | $1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $324.0M | ||
| Q4 25 | $196.9M | $327.5M | ||
| Q3 25 | $179.5M | $340.4M | ||
| Q2 25 | $181.1M | $307.5M | ||
| Q1 25 | $168.9M | $280.5M | ||
| Q4 24 | $187.3M | $229.6M | ||
| Q3 24 | $168.6M | $125.3M | ||
| Q2 24 | $178.0M | $267.0M |
| Q1 26 | $2.9M | $73.8M | ||
| Q4 25 | — | $100.7M | ||
| Q3 25 | $5.4M | $105.2M | ||
| Q2 25 | $-4.8M | $77.3M | ||
| Q1 25 | $4.8M | $47.0M | ||
| Q4 24 | — | $71.0M | ||
| Q3 24 | $-143.5M | $-61.3M | ||
| Q2 24 | $18.9M | $41.7M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 40.4% | ||
| Q3 25 | 3.5% | 40.5% | ||
| Q2 25 | 4.7% | 33.2% | ||
| Q1 25 | 1.2% | 21.6% | ||
| Q4 24 | 13.2% | 40.7% | ||
| Q3 24 | -82.8% | -63.8% | ||
| Q2 24 | 15.9% | 21.9% |
| Q1 26 | 1.6% | 22.8% | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | 3.0% | 30.9% | ||
| Q2 25 | -2.7% | 25.2% | ||
| Q1 25 | 2.8% | 16.8% | ||
| Q4 24 | — | 30.9% | ||
| Q3 24 | -85.1% | -48.9% | ||
| Q2 24 | 10.6% | 15.6% |
| Q1 26 | $0.07 | $1.56 | ||
| Q4 25 | $0.05 | $2.11 | ||
| Q3 25 | $0.12 | $2.18 | ||
| Q2 25 | $-0.11 | $1.58 | ||
| Q1 25 | $0.10 | $0.92 | ||
| Q4 24 | $0.38 | $1.43 | ||
| Q3 24 | $-3.11 | $-1.41 | ||
| Q2 24 | $0.39 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | — |
| Total DebtLower is stronger | — | $878.3M |
| Stockholders' EquityBook value | $653.9M | $3.6B |
| Total Assets | $1.2B | $33.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
| Q1 26 | — | $878.3M | ||
| Q4 25 | $372.2M | $620.6M | ||
| Q3 25 | $376.7M | $620.4M | ||
| Q2 25 | $580.5M | $620.3M | ||
| Q1 25 | $583.4M | $660.5M | ||
| Q4 24 | $585.3M | $660.3M | ||
| Q3 24 | — | $660.2M | ||
| Q2 24 | — | $660.0M |
| Q1 26 | $653.9M | $3.6B | ||
| Q4 25 | $693.1M | $3.6B | ||
| Q3 25 | $727.2M | $3.6B | ||
| Q2 25 | $757.8M | $3.5B | ||
| Q1 25 | $798.5M | $3.4B | ||
| Q4 24 | $778.3M | $3.4B | ||
| Q3 24 | $749.6M | $3.4B | ||
| Q2 24 | $879.3M | $3.2B |
| Q1 26 | $1.2B | $33.5B | ||
| Q4 25 | $1.3B | $31.5B | ||
| Q3 25 | $1.3B | $32.5B | ||
| Q2 25 | $1.5B | $31.9B | ||
| Q1 25 | $1.6B | $31.4B | ||
| Q4 24 | $1.6B | $30.7B | ||
| Q3 24 | $1.5B | $31.6B | ||
| Q2 24 | $1.6B | $29.9B |
| Q1 26 | — | 0.24× | ||
| Q4 25 | 0.54× | 0.17× | ||
| Q3 25 | 0.52× | 0.17× | ||
| Q2 25 | 0.77× | 0.18× | ||
| Q1 25 | 0.73× | 0.19× | ||
| Q4 24 | 0.75× | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TCBI
Segment breakdown not available.
